Article: Isolagen Offering Raises $59.5M For Autologous Cellular Therapies.

Staff Writer

Tissue-regeneration company Isolagen Inc. brought in $59.5 million in a follow-on offering Thursday, leaving it with wrinkle-free plans to begin pivotal trials and bring its lead anti-aging product to the market.

The Houston-based company offered 7 million shares at $8.50 each, a slight discount. Isolagen's stock (AMEX:ILE) dropped 2 cents Thursday to close at $8.97.

It expects to use the estimated net proceeds of $55.4 million, not including any funds from an overallotment option, to expand its manufacturing capabilities in the U.S. and Europe. About $28 million is earmarked for that, while another $10 million is set aside so the ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!